静脉甲泼尼龙后高剂量泼尼松龙改善特发性间质性肺炎急性加重预后
结果显示中位生存时间49天,高剂量泼尼松龙≥0.6 mg/kg是无正压通气患者的显著预后因素,推荐静脉高剂量甲泼尼龙后使用该剂量。
要点
- 急性加重特发性间质性肺炎中位生存时间仅49天,预后差。
- 未用正压通气者中,泼尼松龙≥0.6 mg/kg是显著预后因素。
- 推荐静脉高剂量甲泼尼龙后给予泼尼松龙≥0.6 mg/kg。
核心结论
- 静脉高剂量甲泼尼龙后泼尼松龙≥0.6 mg/kg应推荐用于特发性间质性肺炎急性加重的治疗。
研究设计与样本
- 采用多变量Cox比例风险回归分析识别预后因素,按HRCT模式分为弥漫型和非弥漫型。
主要发现
- 急性加重诊断后中位生存时间为49天,IPF组39天,非IPF组49天。
- 全部患者中,弥漫性HRCT模式、较低血清IgG、较高血清表面活性蛋白D、急性加重前长期氧疗及急性加重时使用正压通气是显著不良预后因素。
- 无正压通气患者中,急性加重前长期氧疗和较低血清IgG是显著不良预后因素。
- 无正压通气患者中,调整其他预后因素后,高剂量泼尼松龙≥0.6 mg/kg是显著预后因素。
关键数值与推荐
- 泼尼松龙初始剂量≥0.6 mg/kg(静脉高剂量甲泼尼龙后使用)为推荐方案。
临床怎么用
- 对特发性间质性肺炎急性加重患者,可考虑静脉高剂量甲泼尼龙后给予泼尼松龙≥0.6 mg/kg,尤其适用于未使用正压通气者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Acute exacerbation (AE) of idiopathic pulmonary fibrosis (IPF) (AE-IPF) is a poor prognostic disorder. AE is also reported to occur in other idiopathic interstitial pneumonias (IIPs). There are limited data available regarding the effectiveness of treatment for AE-IIPs. The objective of this study was to clarify the prognostic impact of the initial dose of prednisolone (PSL) for treating AE-IIPs. METHODS: Eighty-five patients with AE-IIPs, diagnosed according to the criteria of the Japanese Respiratory Society, were enrolled in this study (IPF/non-IPF: 63/22 patients) from 2004 to 2013. We performed multivariate Cox proportional hazard regression analysis to identify poor prognostic factors. HRCT patterns at the onset of AE-IIPs were classified as diffuse or non-diffuse. We evaluated the prognostic significance of the initial dose of PSL by adjusting for other prognostic factors. RESULTS: Median survival time (MST) after AE-IIPs diagnosis was 49 days. MST of AE-IPF and AE-non-IPF was 39 and 49 days, respectively. A diffuse HRCT pattern, lower serum IgG and higher serum surfactant protein-D at AE diagnosis, long-term oxygen therapy (LTOT) before AE and positive pressure ventilation (PPV) use for AE were significant poor prognostic factors for all patients, as were LTOT before AE and lower serum IgG for no-PPV patients. High-dose PSL ≥ 0.6 mg/kg was a significant prognostic factor for no-PPV patients after adjusting for other prognostic factors. CONCLUSION: We concluded that a dose of PSL ≥ 0.6 mg/kg after i.v. high-dose methylprednisolone therapy should be recommended for the treatment of AE-IIPs.
引用
- Arai T, Tachibana K, Sugimoto C, et al. High-dose prednisolone after intravenous methylprednisolone improves prognosis of acute exacerbation in idiopathic interstitial pneumonias. Respirology. 2017. PMID: 28508494. doi:10.1111/resp.13065
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。